Oncology NEWS International
SAN DIEGO-A novel compound, KXO1 (KX2-391) that targets Src family kinases (SFK) inhibited the growth of many cancer cell types in culture and inhibited the growth of human colon cancer cells in animal models, Irwin H. Gelman, PhD, reported at AACR 2008 (abstract 4983).
SAN DIEGO-A novel compound, KXO1 (KX2-391) that targets Src family kinases (SFK) inhibited the growth of many cancer cell types in culture and inhibited the growth of human colon cancer cells in animal models, Irwin H. Gelman, PhD, reported at AACR 2008 (abstract 4983). Dr. Gelman is with the Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York.
Human colon cancer cells, known to have high levels of SFK, can be inhibited by at least 70% by a 1-month regimen of daily oral KXO1 treatments, compared with animal models receiving placebo, he said. The agent, being developed by Kinex Pharmaceuticals, LLC, is currently in phase I trials at M.D. Anderson Cancer Center and Roswell Park.
almost 18 years ago
Immunotherapy agent promising in NSCLCabout 18 years ago
NCCN greenlights nilotinib for imatinib-resistant CML patientsabout 18 years ago
No overall survival benefit for dose-intense regimen in SCLCabout 18 years ago
Make a note of new smoking cessation codesabout 18 years ago
Relistor for treating OICabout 18 years ago
Experts argue against need for phase III proton Rx trialsabout 18 years ago
Spotlight on Cancer Centersabout 18 years ago
Novel peptide vaccine promising in myeloid leukemiaabout 18 years ago
Intensive imatinib/chemo ups EFS in pediatric Ph+ ALL
